3.71
-0.07(-1.85%)
Currency In USD
| Previous Close | 3.78 |
| Open | 3.75 |
| Day High | 3.81 |
| Day Low | 3.67 |
| 52-Week High | 4.13 |
| 52-Week Low | 0.69 |
| Volume | 2.49M |
| Average Volume | 7.03M |
| Market Cap | 732.84M |
| PE | -6.87 |
| EPS | -0.54 |
| Moving Average 50 Days | 3.11 |
| Moving Average 200 Days | 1.92 |
| Change | -0.07 |
If you invested $1000 in Esperion Therapeutics, Inc. (ESPR) 10 years ago, it would be worth $154.71 as of December 17, 2025 at a share price of $3.71. Whereas If you bought $1000 worth of Esperion Therapeutics, Inc. (ESPR) shares 5 years ago, it would be worth $125.25 as of December 17, 2025 at a share price of $3.71.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
GlobeNewswire Inc.
Nov 21, 2025 1:00 PM GMT
– Company to Receive $90 Million Total Payment – – Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL – ANN ARBOR, Mich., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR)
Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference
GlobeNewswire Inc.
Nov 19, 2025 1:00 PM GMT
ANN ARBOR, Mich., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will present at the Piper Sandler 37th Annual Healthcare Conference in New York on December 3, 2025, at 3:30 p.m. ET. The live webcast can
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
GlobeNewswire Inc.
Nov 18, 2025 12:00 PM GMT
ANN ARBOR, Mich., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that HLS Therapeutics Inc. (TSX: HLS), the Company’s partner in Canada for the development and commercialization of NILEMDO® (bempedoic acid) and NEXLIZET®